PUBLISHER: DelveInsight | PRODUCT CODE: 1656902
PUBLISHER: DelveInsight | PRODUCT CODE: 1656902
Transdermal Drug Delivery Devices Market by Type (Drug-in-adhesive Patches, Matrix Patches, Reservoir Membrane Patches, and Microneedle Patches), Application (Pain Management, Central Nervous System Disorders, Hormonal Applications, Cardiovascular Disorders, and Others), End-User (Hospitals, Ambulatory Surgical Centers, and Others), and Geography (North America, Europe, Asia-Pacific, and Rest of the World) is expected to grow at a steady CAGR forecast till 2032 owing to the increasing prevalence of chronic conditions, increase in adoption of third-generation transdermal drug delivery devices, technological advancements observed in the device, and use of these devices from hormonal disorders to cardiovascular conditions and pain management across the globe.
The transdermal drug delivery devices market was valued at USD 71,566.27 million in 2024, growing at a CAGR of 6.91% during the forecast period from 2025 to 2032 to reach USD 121,798.76 million by 2032. The growing prevalence of chronic conditions, coupled with the increasing adoption of third-generation transdermal drug delivery devices, is significantly boosting the global market for these devices. Technological advancements have enhanced device efficiency, improving drug absorption and patient convenience. Their versatile application across hormonal disorders, cardiovascular conditions, and pain management further drives demand, offering a non-invasive, controlled, and patient-friendly alternative for drug delivery. Together, these factors contribute to the expanding use and development of transdermal drug delivery devices worldwide during the forecast period from 2025 to 2032.
Transdermal Drug Delivery Devices Market Dynamics:
According to recent data provided by the British Heart Foundation (2024), globally, approximately 620 million people, or about 1 in 13 individuals, live with heart and circulatory diseases.
Furthermore, as per the recent data provided by the British Heart Foundation (2024), coronary (ischemic) heart disease, the most commonly diagnosed worldwide, affects an estimated 200 million people globally. Approximately 110 million men and 80 million women are affected. Additionally, around 56 million women and 45 million men are stroke survivors. It is estimated that at least 13 million people worldwide live with congenital heart disease, with potentially millions more undiagnosed. As the prevalence of CVDs rises globally, particularly among aging populations and individuals with sedentary lifestyles, the need for convenient, long-term treatment solutions has intensified. Thus, transdermal drug delivery devices allow for controlled and consistent delivery of medications like antihypertensives, antianginal drugs, and anticoagulants, ensuring better therapeutic outcomes and improved patient compliance thereby boosting the overall market across the globe.
Additionally, as per the recent data provided by the World Health Organization (2024), epilepsy affects approximately 50 million people worldwide, making it one of the most prevalent neurological disorders globally. Thus, with the rising prevalence of neurological disorders, there is a growing demand for non-invasive and effective treatment methods. These transdermal drug delivery devices provide controlled and consistent delivery of medications, bypassing the gastrointestinal tract and reducing side effects often associated with oral or injectable therapies thereby boosting the market of transdermal drug delivery devices across the globe.
Additionally, the increase in strategic activities among the key market players is further boosting the market of transdermal drug delivery devices across the globe. For instance, in January 2024, Starton Therapeutics announced the launch of STARSILON a novel proprietary transdermal patch delivery platform.
Thus, the factors mentioned above are expected to boost the overall market of transdermal drug delivery devices across the globe during the forecast period from 2025 to 2032.
However, disadvantages associated with transdermal drug delivery devices such as irritation at the site of application edema and increased product recalls may hinder the future market of transdermal drug delivery devices across the globe during the forecasted period.
Transdermal Drug Delivery Devices Market Segment Analysis:
Transdermal Drug Delivery Devices Market by Type (Drug-in-adhesive Patches, Matrix Patches, Reservoir Membrane Patches, and Microneedle Patches), Application (Pain Management, Central Nervous System Disorders, Hormonal Applications, Cardiovascular Disorders, and Others), End-User (Hospitals, Ambulatory Surgical Centers, and Others), and Geography (North America, Europe, Asia-Pacific, and Rest of the World)
The drug-in-adhesive patches category in the transdermal drug delivery devices market is estimated to dominate the market with a market share of 55.44% in 2024. This can be attributed to the various advantages and applications provided by these adhesive patches which will be responsible for driving the demand for transdermal drug delivery devices market during the given forecast period. Drug-in-adhesive transdermal patches are a type of drug delivery system designed to deliver drugs through the skin and into the bloodstream. These patches are designed to release the drug over time, providing a controlled and consistent therapeutic dosage. The adhesive layer adheres the patch to the skin and also helps to control the rate at which the drug is released. When the patch is applied to the skin, the drug gradually diffuses through the skin and into the bloodstream, providing a steady and controlled release of medication over time.
Drug-in-adhesive transdermal patches are easy to apply and do not require needles or invasive procedures, making them more convenient and patient-friendly. These drug delivery systems provide a controlled and consistent release of medication over a prolonged period, which helps to maintain stable drug levels in the bloodstream. Further presence of some key products in the market such as TRANSDERM-V by Novartis and Mylan-rivastigmine Patch 10 by Viatris Inc. will also contribute in propelling the growth of this category.
Hence, owing to the above-mentioned factors, the market for drug-in-adhesive will experience increased demand, thus driving the overall transdermal drug delivery devices market during the forecast period.
North America is expected to dominate the overall transdermal drug delivery devices market:
Among all regions, North America is estimated to hold the largest share of 45.39% in the global transdermal drug delivery devices market in 2024, growing at a CAGR of 5.91% during the forecast period from 2025 to 2032. This can be attributed to the growing prevalence of targeted diseases such as chronic pain, central nervous system disorders, and cardiovascular diseases in the region, new product launches, and the increased focus on research and development activities among other factors that are driving the overall growth of the transdermal drug delivery devices market over the forecast period.
According to recent data from the Centers for Disease Control and Prevention (2024), approximately 4.9% of adults were diagnosed with coronary heart disease in 2022. Furthermore, by 2023, an estimated 12.1 million individuals in the United States were projected to have atrial fibrillation. Additionally, each year, over 795,000 people in the U.S. experience a stroke, with around 610,000 of these being first-time strokes. Notably, nearly 185,000 of these strokes, or about one in four, occur in individuals who have previously had a stroke.
Additionally, as per the recent data provided by the Alzheimer's Association, in 2024, approximately 6.9 million Americans age 65 and older are living with Alzheimer's. Furthermore, as per the recent data provided by the Parkinson's Foundation (2022), nearly 90,000 people are diagnosed with Parkinson's disease in the U.S. each year and approximately one million people in the U.S. are living with Parkinson's disease (PD). This number is expected to rise to 1.2 million by 2030. Thus, the rising prevalence of these diseases, coupled with the demand for patient-friendly solutions that improve adherence and reduce systemic side effects, is accelerating the adoption of transdermal technologies.
Furthermore, the increasing number of product development activities in the region is further going to accelerate the growth of the spinal non-fusion devices market. For instance, in February 2024, LTS LOHMANN Therapie-Systeme AG announced the launch of the UDENYCA(R) on-body injector (OBI) through its Sorrel(TM) platform. UDENYCA(R) (pegfilgrastim-cbqv) aims to reduce infection risks post-chemotherapy. The FDA approved the device in December 2023, enhancing patient convenience and drug administration at home.
Thus, the above-mentioned factors are expected to escalate the market of transdermal drug delivery devices in the region.
Transdermal Drug Delivery Devices Market Key Players:
Some of the key market players operating in the transdermal drug delivery devices market include Novartis, Viatris Inc., UCB SA, Hisamitsu Pharmaceutical, Boehringer Ingelheim, Johnson & Johnson Services Inc., Purdue Pharma, Bayer AG, Haleon Group of Companies, Ingenus Pharmaceuticals, Luye Pharma Group, Cumberland Pharmaceuticals Inc., Sanofi, Sparsha Pharma International Pvt Ltd., Cipla, and others.
Recent Developmental Activities in the Transdermal Drug Delivery Devices Market:
Key Takeaways From the Transdermal Drug Delivery Devices Market Report Study
Target Audience Who Can be Benefited From This Transdermal Drug Delivery Devices Market Report Study
Frequently Asked Questions for the Transdermal Drug Delivery Devices Market: